SCHEMBL688513

SCHEMBL688513

O=C(NCc1cccc(Cl)c1)NC(=O)N(C1CCCCC1)C1CCCCC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.52
ALOX12 P18054 1/20 0.52
EPHX2 P34913 3/20 0.49
F2 P00734 4/20 0.47
LMNA P02545 2/20 0.46
RXFP1 Q9HBX9 2/20 0.46
TP53 P04637 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
KMT2A Q03164 1/20 0.45
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
EPHX1 P07099 2/20 0.44
GLA P06280 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL688704 0.79 NAMPT (0.57) MAPTKMT2AALDH1A1GAAL3MBTL1
SCHEMBL687593 0.78 SMN1; SMN2 (0.54) MAPTLMNAHTTNPSR1ALDH1A1
SCHEMBL688798 0.75 SMN1; SMN2 (0.64) EPHX2KMT2AALDH1A1
SCHEMBL689048 0.72 HPGD (0.57) KMT2AALDH1A1GAAL3MBTL1
SCHEMBL12384849 0.71 NPSR1 (0.48) MAPTEPHX2F2LMNAHTT
SCHEMBL9071835 0.71 NPSR1 (0.48) MAPTEPHX2F2LMNAHTT
SCHEMBL18125472 0.71 MAPT (0.41) MAPTEPHX2LMNARXFP1HTT
SCHEMBL2470608 0.71 POLB (0.64) MAPTALOX12F2RXFP1KMT2A
SCHEMBL19975182 0.70 ALDH1A1 (0.48) MAPTALOX12EPHX2F2LMNA
SCHEMBL13647316 0.70 GAA (0.54) EPHX2RXFP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904438-B1 DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS NOVO NORDISK AS (DK) 2012-02-29 EP claimed
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators NOVO NORDISK A/S (DK) 2008-12-25 US claimed
EP-1904438-B1 DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS NOVO NORDISK AS (DK) 2012-02-29 EP disclosed
US-7999114-B2 Dicycloalkylcarbamoyl ureas as glucokinase activators NOVO NORDISK A/S (DK) 2011-08-16 US disclosed
US-7999114-B2 Dicycloalkylcarbamoyl ureas as glucokinase activators NOVO NORDISK A/S (DK) 2011-08-16 US disclosed
US-7999114-B2 Dicycloalkylcarbamoyl ureas as glucokinase activators NOVO NORDISK A/S (DK) 2011-08-16 US disclosed
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators NOVO NORDISK A/S (DK) 2008-12-25 US disclosed
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators NOVO NORDISK A/S (DK) 2008-12-25 US disclosed
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators NOVO NORDISK A/S (DK) 2008-12-25 US disclosed
WO-2007006761-A1 DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators GCK, HK1, GCKR MAPT 1211/4885ALOX12 3523/4885EPHX2 4136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.